Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 2, February, p. 257–264

doi: 10.17219/acem/115238

Publication type: review article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Pulmonary rehabilitation in interstitial lung diseases: A review of the literature

Krzysztof Wytrychowski1,A,B,C,D,F, Anna Hans-Wytrychowska2,A,B,D,E, Paweł Piesiak3,B,C,E, Marta Majewska-Pulsakowska4,A,B,C,D,E, Krystyna Rożek-Piechura5,E,F

1 Department and Clinic of Internal Medicine, Pneumonology and Allergology, Wroclaw Medical University, Poland

2 Department of Family Medicine, Wroclaw Medical University, Poland

3 Department and Clinic of Pulmonology and Lung Cancers, Wroclaw Medical University, Poland

4 Department and Division of Medical Rehabilitation, Wroclaw Medical University, Poland

5 Department of Rehabilitation in Internal Diseases, University School of Physical Education, Wrocław, Poland

Abstract

There are more than 200 different diseases classed as interstitial lung diseases (ILDs). For epidemiological and practical purposes, ILDs are classified into diseases of known and unknown etiology. The aim of this review is to evaluate our current knowledge about the efficacy and safety of pulmonary rehabilitation (PR) in patients with ILDs. Other issues, such as ILD pathogenesis, prevalence and comorbidity, are also elaborated in the review. Pulmonary rehabilitation is an important part of comprehensive care for patients with ILDs. In comparison to PR for patients with chronic pulmonary obstructive disease (COPD), the number of clinical studies concerning PR for patients with ILDs is small. The majority of trials have been performed in relatively small groups of patients. The principles of PR in this group of patients are the same as for patients with COPD. Exercise-induced desaturation is frequently observed during PR, which is the main source of complications in patients with ILDs. Major differences between ILD and COPD patients include poorer exercise tolerance and faster development of respiratory failure in patients with ILDs.

Key words

pulmonary rehabilitation, airway management, interstitial lung diseases

References (42)

  1. Wiatr E. Definicja i klasyfikacje chorób śródmiąższowych płuc. In: Wiatr E, Rowińska-Zakrzewska E, Pirożyński M, eds. Choroby śródmiąższowe płuc. Bielsko-Biała, Poland: Alfa Medica Press; 2012:15–20.
  2. Boros P. Zaburzenia czynnościowe w chorobach śródmiąższowych płuc. In: Wiatr E, Rowińska-Zakrzewska E, Pirożyński M, eds. Choroby śródmiąższowe płuc. Bielsko-Biała, Poland: Alfa Medica Press; 2012:48–61.
  3. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50(2). pii: 1602419. doi:10.1183/13993003.02419-2016
  4. Interstitial Lung Diseases – ERS. https://www.erswhitebook.org/chapters/interstitial-lung-diseases/.
  5. Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014;2:4. doi:10.1186/2213-0802-2-4
  6. Loveman E, Copley VR, Colquitt J, et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: A systematic review and economic evaluation. Health Technol Assess. 2015;19(20):i–xxiv,1–336.
  7. Nici L, Donner C, Wouters E, et al; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390–1413.
  8. Spruit MA, Singh SJ, Garvey C, et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2013;188(8):1011–1027.
  9. Rochester CL, Vogiatzis I, Holland AE, et al; ATS/ERS Task Force on Policy in Pulmonary Rehabilitation. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373–1386.
  10. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Respir Med. 2008;102(12):1675–1680.
  11. Flaherty KR, Thwaite E, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: Survival implications. Thorax. 2003;58(2):143–148.
  12. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–554.
  13. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–399.
  14. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008;4:CD006322.
  15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med. 2002;166(1):111–117.
  16. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231–1237.
  17. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med. 2009;103(10):1430–1435.
  18. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: A systematic review of the literature. Thorax. 2013;68(9):867–879.
  19. Swigris JJ, Fairclough DL, Morrison M. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56(6):783–789.
  20. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;10:CD006322.
  21. Gomes-Neto M, Silva CM, Ezequiel D, Conceição CS, Saquetto M, Machado AS. Impact of pulmonary rehabilitation on exercise tolerance and quality of life in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. J Cardiopulm Rehabil Prev. 2018;38(5):273–278.
  22. Huppmann P, Szczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42(2):444–453.
  23. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803–809.
  24. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164(5):551–556.
  25. King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19(5):466–473.
  26. Sherner J, Collen J, King CS, Nathan SD. Pulmonary hypertension in idiopathic pulmonary fibrosis: Epidemiology, diagnosis and therapeutic implications. Curr Respir Care Rep. 2012;1(4):233–242.
  27. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114(14):1482–1489.
  28. de Man FS, Handoko ML, Groepenhoff H, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;34(3):669–675.
  29. Fox BD, Kassirer M, Weiss I, et al. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. J Card Fail. 2011;17(3):196–200.
  30. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respiro­logy. 2014;19(8):1215–1221.
  31. Cottin V, Nunes H, Brillet P-Y, Delaval P. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593.
  32. Holland AE, Hill CJ, Glaspole I, Goh N, Mc-Donald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012;106(3):429–435.
  33. Deniz S, Şahin H, Yalnız E. Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation? Clin Respir J. 2018;12(6):2141–2150.
  34. Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study. Respir Med. 2014;108(1):203–210.
  35. Perez-Bogerd S, Wuyts W, Barbier V, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: A randomised controlled trial. Respir Res. 2018;19(1):182.
  36. da Fontoura FF, Berton DC, Watte G, et al. Pulmonary rehabilitation in patients with advanced idiopathic pulmonary fibrosis referred for lung transplantation. J Cardiopulm Rehabil Prev. 2018;38(2):131–134.
  37. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–399.
  38. Leach RM, Davidson AC, Chinn S, Twort CH, Cameron IR, Bateman NT. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax. 1992;47(10):781–789.
  39. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Statement. Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011;183(6):788–824.
  40. Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: Benefits and predictors of response. Chest. 2009;135(2):442–447.
  41. Keyser RE, Christensen EJ, Chin LM, Woolstenhulme JG. Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease. Respir Med. 2015;109(4):517–525.
  42. Vainshelboim B, Myers J, Oliveira J, Izhakian S, Unterman A, Kramer MR. Physiological responses and prognostic value of common exercise testing modalities in idiopathic pulmonary fibrosis. J Cardio­pulm Rehabil Prev. 2018 Sep 24 [Epub ahead of print]. doi:10.1097/HCR.0000000000000362
© Wroclaw Medical University